Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) FCF Margin (2024 - 2025)

Silence Therapeutics (SLN) has disclosed FCF Margin for 2 consecutive years, with 50844.12% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 5073527.0% to 50844.12% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 11649.72% through Dec 2025, down 1149303.0% year-over-year, with the annual reading at 11149.55% for FY2025, 1099270.0% down from the prior year.
  • FCF Margin hit 50844.12% in Q4 2025 for Silence Therapeutics, down from 6847.17% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 58.24% in Q1 2024 to a low of 50844.12% in Q4 2025.